Five things for pharma marketers to know: Friday,  October 17

Five things for pharma marketers to know: Friday, October 17


Amgen sues Sanofi and Regeneron over PCSK9 patents; FDA panel wants Chantix black box to stay; Valeant-Allergan uproar rises in pitch; Pharmacyclics and Roche team up against CLL; and GSK's Ebola vax may "miss" the current crisis.

Five things for pharma marketers to know: Friday, September 19

Five things for pharma marketers to know: Friday, September 19


Lilly's weekly GLP-1 shot is approved, BI expands its lung-cancer portfolio, GSK's China investigation closes, NY proposed Sovaldi triage and India imposed price limits on 36 new medicines.

NY sues over Forest Alzheimer's medication

NY's attorney general alleges that a formulation switch is an attempt to create monopoly.

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, August 29

By By

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

J&J, Vivus patent suit ends

J&J subsidiary Janssen has abandoned its patent lawsuit over the anti-seizure medication topiramate, which is part of Vivus's prescription weight-loss drug Qsymia.

Chicago sues painkiller companies

The Windy City seeks $9.5 million in damages in a lawsuit that accuses manufacturers of misleading consumers.

CA counties sue makers of painkillers

Orange and Santa Clara counties are suing painkiller makers like Purdue and Endo, a suit akin to deceptive ad cases launched against the tobacco industry.

Astellas, DOJ settle for $7.3M

Astellas, DOJ settle for $7.3M


Astellas has settled a False Claims case with the Department of Justice over the 2010-2013 marketing of an antifungal medication. Astellas denies the allegations.

Louisiana sends Takeda $9-billion Actos bill

The drugmaker is accused of burying cancer risks associated with the diabetes medication.

Healthcare reform lawsuits continue

With just days before the enrollment deadline, courts are pulsing with legal opposition to heatlhcare reform insurance subsidies.

Court reverses Risperdal decision

The Arkansas Supreme Court's decision puts $1.2 billion back into J&J's coffers.

Hawaii sues BMS, Sanofi over Plavix

The state's attorney general says the drugmakers did not reveal that the drug could have a different impact—if any—on patients with East Asian or Pacific Islander heritage.

Ranbaxy, Teva settle with New York State

The drugmakers admitted no wrongdoing, but are paying the state $300,000 over an agreement not to challenge generics filings.

Merck may be near NuvaRing settlement

The drugmaker may be able to settle around 3,800 cases for $100 million.

J&J unit destroyed documents

The Star-Ledger reports that the company's Ethicon unit destroyed development documents about its vaginal mesh products as a matter of course. The company's West Virginia legal scuffle over the product begins Monday.

US accuses Novartis of kickback scheme

The complaint centers around iron-control drug Exjade.

Judge slaps Boehringer with $931K fine

The fine is for Pradaxa documents that have gone missing. The company is accused of hiding risk information about its blood thinner.

Lawsuits cause J&J to open its checkbook

The company is paying $2.5 billion over its DePuy hip replacements and $11 million in a lawsuit over its seizure drug Topamax.

J&J marketing triggers $2.2B payout

J&J marketing triggers $2.2B payout


The company will shell out $2.2 billion over allegations of marketing misconduct for Risperdal, Invega and Natrecor.

Business briefs: Abbott, IMS Health, Boehringer, plus healthcare reform

Abbott's Depakote lawsuits roll on; IMS buys mobile health firm's assets; BI shutters a chemical plant; and the healthcare reform back-and-forth continues.

Business briefs: Pfizer, GlaxoSmithKline, AstraZeneca, Mallinckrodt

Pfizer settles Rapamune lawsuits; Moody's downgrades GSK; Astrazeneca pursues anemia medication; Mallinckrodt drugs gets priority review

Business briefs: Healthcare reform, J&J, Lilly, Quest

The healthcare reform information campaign continues; J&J settles a shareholder lawsuit; Eli Lilly freezes company salaries; and Quest dumps cancer med royalty rights.

Hot-flash med could open up women's health category

Hot-flash med could open up women's health category


The first prescription non-hormonal treatment offers relief for women who do not want to tangle with hormone-replacement therapy.

Novartis sued for alleged speaker-program abuse


The Swiss drug maker is defending itself against two civil fraud lawsuits filed within a week of each other.

Novartis: lawsuits, layoffs and, by the way, earnings


It was an all-in-one news day for the drug maker which, by the way, saw sales rise 2% for the first quarter, compared to the same period last year.

Business briefs: Chandler Chicco, Pfizer, FDA, Dainippon, CDC

Gwee exchanges Edelman offices for Chandler Chicco's, Pfizer can't shake Celebrex lawsuits, FDA issues draft guidance for biosimilars meetings, Dainippon Sumitomo acquires Edison Pharmaceuticals, CDC reports on growing ADHD diagnoses.

Business briefs: Endo; Allergan

Endo gets a new president, Allergan settles a Botox case

Company news: Elsevier, Abbott, Genzyme

Elsevier launches new drug class overviews, a whistleblower accuses Abbott and Genzyme clears the way for Lemtrada.

Company news: J&J, Novartis, Astellas

J&J is said to be circling a Risperdal settlement, Novartis links up with UPenn to fight cancer, and Astellas puts 13 scientists out of work.

Email Newsletters